Press Releases

Press Releases

March 1, 2019
First and only therapy approved for FCS, a serious and rare disease with no approved treatment options BOSTON, Mass. and CARLSBAD, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals,
February 28, 2019
Planned activities to highlight wide-ranging impact of rare diseases on patients and challenges in disease management, including important perspectives from caregivers BOSTON , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
February 26, 2019
TEGSEDI™ (inotersen) commercially available in United States , European Union & Canada Achieved Fourth Quarter 2018 TEGSEDI® (inotersen) Global Net Product Revenues of $2.2 Million Conference Call Webcast Tuesday, February 26 , 4:30 p.m. ET at www.akceatx.com   BOSTON , Feb.
February 25, 2019
Phase 3 planning and initiation activities underway Akcea earns $150M license fee BOSTON and CARLSBAD, Calif., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that
February 20, 2019
BOSTON , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company overview at the
February 13, 2019
Webcast scheduled for Tuesday, February 26th at 4:30 p.m. Eastern Time BOSTON , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , announced today that it will host a live webcast on Tuesday, February 26 th at 4:30 p.m.
November 29, 2018
Presentations focus on the benefits of treatment with TEGSEDI™ (inotersen) and results show continued efficacy with long-term exposure in the NEURO-TTR open-label extension study BOSTON , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis
November 12, 2018
Approximately 98% of patients receiving highest dose achieved reductions in Lp(a) levels below the established threshold of risk for CVD events Favorable safety and tolerability profile observed in largest study ever conducted in patients with cardiovascular disease and elevated Lp(a) BOSTON and
November 8, 2018
Results to be presented show a significant reduction of Lp(a) levels, favorable safety and tolerability profile BOSTON and CARLSBAD, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals,
November 6, 2018
BOSTON , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that management will present a company overview at the